Editas Medicine (EDIT) Projected to Post Quarterly Earnings on Wednesday

Key Points

• Editas Medicine is set to announce its Q2 2025 earnings on August 6th, with analysts expecting a loss of ($0.40) per share and revenue of $1.81 million.
• In its last earnings report, Editas surpassed expectations with a reported loss of ($0.43) EPS and generated revenue of $4.66 million, significantly exceeding analyst forecasts.
• The stock currently holds a market capitalization of $216.81 million and has seen various analysts adjusting their ratings to a consensus target price of $4.70.

Editas Medicine (NASDAQ:EDIT - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 6th. Analysts expect Editas Medicine to post earnings of ($0.40) per share and revenue of $1.81 million for the quarter.

Editas Medicine (NASDAQ:EDIT - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.08. The company had revenue of $4.66 million during the quarter, compared to analysts' expectations of $0.79 million. Editas Medicine had a negative return on equity of 139.24% and a negative net margin of 701.06%. During the same period in the prior year, the company earned ($76.00) EPS. On average, analysts expect Editas Medicine to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Editas Medicine Trading Down 2.8%

NASDAQ:EDIT traded down $0.07 during trading hours on Friday, hitting $2.44. 1,621,020 shares of the company were exchanged, compared to its average volume of 2,645,013. The stock has a market capitalization of $204.25 million, a price-to-earnings ratio of -0.80 and a beta of 2.19. Editas Medicine has a one year low of $0.91 and a one year high of $5.09. The company has a fifty day simple moving average of $2.40 and a 200 day simple moving average of $1.78.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Wall Street Zen raised Editas Medicine from a "sell" rating to a "hold" rating in a research report on Saturday, July 26th. Cantor Fitzgerald upgraded Editas Medicine from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 29th. HC Wainwright initiated coverage on Editas Medicine in a report on Monday, April 28th. They set a "buy" rating and a $3.00 price target for the company. Finally, Robert W. Baird decreased their price target on Editas Medicine from $8.00 to $4.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $4.70.

Insider Activity at Editas Medicine

In other Editas Medicine news, CEO Gilmore Neil O'neill sold 15,192 shares of Editas Medicine stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $1.72, for a total transaction of $26,130.24. Following the completion of the transaction, the chief executive officer owned 280,282 shares in the company, valued at approximately $482,085.04. The trade was a 5.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last three months, insiders sold 16,364 shares of company stock valued at $28,146. Company insiders own 2.10% of the company's stock.

Hedge Funds Weigh In On Editas Medicine

An institutional investor recently raised its position in Editas Medicine stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 122.2% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 2,600,000 shares of the company's stock after purchasing an additional 1,430,000 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 3.11% of Editas Medicine worth $3,016,000 as of its most recent SEC filing. 71.90% of the stock is owned by institutional investors.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.